Access program for secukinumab (Cosentyx) when other treatments fail
Treatments studied
Part of Infections, Skin clinical trials.
This program gives access to a medicine called secukinumab (brand name Cosentyx) for people with serious conditions who have run out of other treatment options and cannot join a clinical trial. It is a special access program for when standard care is not enough.
Summary written for real people, not researchers, by Clin2.
Who can take part
- A licensed doctor must request this treatment for you.
- You must have a serious or life-threatening condition with no other satisfactory treatment options available, or you cannot take the available ones.
- You are not eligible for or unable to join a Novartis clinical trial.
- Your doctor must believe the treatment could benefit you and that the risks are not unreasonable.
- You must meet any other medical criteria set by the health authority in your country.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a drug called secukinumab (a type of biologic that targets inflammation) for people with moderate to severe hidradenitis suppurativa (HS). It may be an option if you have tried other treatments and they didn't work well.
This study tests whether applying secukinumab as a topical cream or as a subcutaneous injection is more effective and safer for treating hidradenitis suppurativa (a skin condition causing painful lumps). It aims to find a better way to manage symptoms in people whose condition has not improved with standard treatments.
This trial tests whether combining the drug secukinumab with surgery can help people with moderate to severe hidradenitis suppurativa (HS). It looks at how well this combination works and if it is safe over a year.
This study tests if a drug called secukinumab (a self-injected biologic) is safe and effective for adults with moderate-to-severe hidradenitis suppurativa (HS) in China. It may help reduce the number of painful HS lesions.
This study measures how satisfied people with moderate to severe hidradenitis suppurativa (HS) feel with their treatment after starting Cosentyx. It is for adults in Saudi Arabia who have not taken Cosentyx before and are starting it as part of their routine care.
This trial tests a new medicine called SCT650C for people with moderate to severe hidradenitis suppurativa (HS). The goal is to see if it can reduce painful bumps and abscesses better than current treatments.
Hear when a new Hidradenitis Suppurativa (HS) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.